CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) had its target price raised by stock analysts at Stifel Nicolaus from $27.00 to $30.00 in a report issued on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective points to a potential downside of 11.76% from the company’s current price.
A number of other research firms also recently weighed in on CLCD. Piper Jaffray Cos. reissued an “overweight” rating and issued a $21.00 target price on shares of CoLucid Pharmaceuticals in a report on Friday, September 9th. Ladenburg Thalmann increased their target price on CoLucid Pharmaceuticals from $23.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, September 6th. Finally, Zacks Investment Research upgraded CoLucid Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 17th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $30.45.
Shares of CoLucid Pharmaceuticals (NASDAQ:CLCD) opened at 34.00 on Monday. CoLucid Pharmaceuticals has a 52-week low of $3.57 and a 52-week high of $35.48. The company has a 50-day moving average price of $13.90 and a 200-day moving average price of $8.85. The company’s market cap is $521.36 million.
CoLucid Pharmaceuticals (NASDAQ:CLCD) last posted its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by $0.22. On average, equities analysts predict that CoLucid Pharmaceuticals will post ($3.91) EPS for the current year.
In related news, CEO Thomas P. Mathers sold 6,000 shares of the stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $23.32, for a total transaction of $139,920.00. Following the completion of the sale, the chief executive officer now owns 244,714 shares in the company, valued at $5,706,730.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder A/S Novo bought 100,000 shares of the business’s stock in a transaction that occurred on Friday, September 9th. The shares were acquired at an average price of $20.00 per share, with a total value of $2,000,000.00. Following the transaction, the insider now directly owns 3,156,563 shares of the company’s stock, valued at approximately $63,131,260. The disclosure for this purchase can be found here. 13.70% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the company. FMR LLC acquired a new stake in CoLucid Pharmaceuticals during the second quarter valued at about $554,000. Vanguard Group Inc. raised its position in shares of CoLucid Pharmaceuticals by 1.2% in the second quarter. Vanguard Group Inc. now owns 76,242 shares of the biopharmaceutical company’s stock worth $623,000 after buying an additional 900 shares during the last quarter. Finally, Societe Generale purchased a new position in shares of CoLucid Pharmaceuticals during the second quarter worth approximately $464,000. Hedge funds and other institutional investors own 36.92% of the company’s stock.
CoLucid Pharmaceuticals Company Profile
CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.
Receive News & Ratings for CoLucid Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.